DexCom, Inc. (NASDAQ:DXCM) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. Wall Street is bullish on DexCom, Inc. (NASDAQ:DXCM) after the company topped revenue and EPS estimates during its fiscal second quarter of 2025. The company posted $1.16 billion in revenue, up 15.21% year-over-year and ahead of consensus by $32.49 million. In addition, the EPS of $0.48 also came in ahead of the expectations by $0.04. Management noted that both the US and International revenue contributed to thi ...

Key Takeaways IART's CSS segment sees strong global demand, boosted by the Acclarent acquisition and international growth.IART's Tissue Technologies gains momentum with Integra Skin, DuraSorb and planned Braintree production.Integra faces macro risks, supply disruptions, tariffs and a stretched liquidity position.Integra LifeSciences Holdings Corporation (IART) is seeing healthy demand for its industry-leading products within the Codman Specialty Surgical (“CSS”) segment. The company is also successfully ex ...

公司产品创新 - 公司推出新一代da Vinci 5平台实时手术洞察功能 通过实时反馈提升手术安全性、精准度和效率[1] - 新软件包含力测量仪和视频回放功能 力测量仪实时显示手术施力程度以减少组织创伤 视频回放支持术中即时复查关键操作环节[10] - 网络CCM功能支持远程更新 使医院无需行政延误即可获得新功能 提升运营效率[11] - 新平台计算能力达前代产品的10,000倍以上 从手术工具转型为学习与性能优化系统[1] 战略与竞争定位 - 软件升级强化平台价值 推动客户深度采用da Vinci 5系统 通过经常性软件收入增强业务韧性[4] - 持续创新策略延伸竞争优势 支持溢价定价并巩固微创护理领域长期增长潜力[4][11] - 平台化演进超越传统手术机器人硬件定位 构建随时间增值的生态系统[9] 财务表现与估值 - 公司市值达1612亿美元 最近季度盈利超预期14.1%[5] - 尽管宣布创新进展 股价当日下跌3.5% 年初至今累计下跌16.9% 同期行业指数下跌10.6% 标普500指数上涨12.7%[3] 行业前景 - 全球手术机器人市场规模2024年达43.1亿美元 预计2030年增至74.2亿美元 2025-2030年复合增长率9.42%[12] - 行业增长动力来自技术创新、全球及地区企业增加投资 以及慢性病与关节置换手术需求上升[12] 同业比较 - 公司当前Zacks评级为3级（持有）[13] - 西氏医药服务第二季度调整后每股收益1.84美元 超预期21.9% 收入7.665亿美元超预期5.4% 长期增长率预期8.5%[14] - Medpace控股第二季度每股收益3.10美元 超预期3.3% 收入6.033亿美元超预期11.5% 长期增长率预期11.4%[15] - Envista第二季度调整后每股收益0.26美元 超预期8.3% 收入6.82亿美元超预期6.3% 长期增长率预期16.8%[16]

   Calgary, Alberta – TheNewswire - September 16, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is excited to announce that it has completed one-month postoperative examinations of the first patients who were implanted with the Ocumetics Accommodating Intraocular Lens in Mexico City on August 15, 2025 (the “Ocumetics Lens”).   “On Friday September 12th, we performed one-month postoperative examinations of ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

公司技术突破 - 公司成功完成全球首例使用SSi Mantra手术机器人系统的儿科肾盂成形远程手术 距离达1000英里 [2] - SSi Mantra系统已累计完成超过50例远程手术 最远距离达4000英里 [5] - 系统配备3-5个模块化机械臂 支持40多种机器人内窥镜手术器械 包含3D 4K监视器和实时影像叠加功能 [7] 临床应用与市场定位 - 手术机器人系统相比传统方法具有更精确 微创 疼痛轻和恢复快的优势 [3] - 公司重点拓展儿科手术机器人市场 计划开发更小型器械以满足儿科需求 [5] - 系统已在印度经过100多种外科手术的临床验证 覆盖心脏 泌尿 妇科 肿瘤和普外科等领域 [7][9] 财务表现 - 公司当期营业收入1000万美元 较上年同期600万美元增长66.7% [1] - 毛利润240万美元 同比增长35.3% 毛利率为24% [1] - 研发投入73万美元 同比增长11.4% 行政费用101万美元 同比增长147% [1] - 净利润33万美元 同比大幅增长518% 基本每股收益0.02美元 [1] 战略发展 - 公司通过远程手术能力拓展农村和偏远地区市场 推动手术机器人技术普及 [3] - 作为总部位于印度的美国公司 计划在全球推广其技术先进 用户友好且成本效益高的手术机器人解决方案 [6]

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now commercially available in the United States, expanding patient and provider access BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorder ...

Showcases SSi Mantra’s strengths in robotic telesurgery and opportunity in pediatricsFORT LAUDERDALE, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the world’s first pediatric pyeloplasty telesurgery has been successfully performed utilizing the Company’s SSi Mantra ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website. The new FAQ resource, available at www.izocorp.c ...

核心观点 - Elutia公司发布临床及临床前数据 支持其抗生素洗脱生物包膜在心脏植入电子设备(CIED)囊袋管理中的临床效用 该技术通过局部抗生素输送解决细菌定植问题 同时促进组织重塑并固定设备 [1][3][4] 临床研究数据 - HEAL研究(NCT04645173)显示 使用工程化细胞外基质(ECM)包膜的患者总体手术难度降低43% 其中发生器移动难度降低46% 导线移动难度降低41% [2] - 生物包膜不仅便于初始放置和设备稳定 还能长期保持囊袋的手术可及性 对可能需要再次干预的患者特别重要 [3] 临床前研究数据 - 临床前研究显示抗生素洗脱包膜能完全根除CIED相关并发症常见细菌接种物 包括MRSA等病原体 同时保持再生功能 [3] - 药代动力学评估证实局部抗生素浓度可持续维持长达两周 [3] 技术平台与应用拓展 - 再生性ECM与广谱协同抗生素(如利福平和米诺环素)结合形成强大平台 适用于组织重塑和感染控制交叉的外科环境 [4] - 公司基于该平台推进下一代产品管线 针对更高风险手术 如三分之一的患者会在重建后出现严重并发症的乳房重建领域 [4] 公司背景 - Elutia专注于开发和商业化药物洗脱生物基质产品 旨在改善医疗设备与患者之间的相容性 [5] - 公司使命是通过人性化医疗使患者能够无妥协地健康成长 [5]